Related Experiment Video

Updated: Jun 30, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

EGFR inhibition as a therapy for head and neck squamous cell carcinoma

Judith Loeffler-Ragg1, Ilona Schwentner, Georg M Sprinzl

  • 1Innsbruck Medical University, Department of Internal Medicine, Anichstrasse 35, 6020 Innsbruck, Austria.

Expert Opinion on Investigational Drugs
|September 24, 2008
PubMed
Abstract

Insights

Targeted therapies like anti-EGFR antibodies show promise for head and neck squamous cell carcinoma (HNSCC). While safe and active in some patients, understanding who benefits from these EGFR-targeted drugs remains key.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Head and neck squamous cell carcinoma (HNSCC) often overexpresses the epidermal growth factor receptor (EGFR).
  • EGFR is a negative prognostic marker in HNSCC, driving the development of targeted therapies.

Purpose of the Study:

  • To review the mechanisms and clinical efficacy of anti-EGFR antibodies and EGFR tyrosine kinase inhibitors.
  • Focus on patients with locally advanced or recurrent/metastatic HNSCC.

Main Methods:

  • Systematic literature review.
  • Analysis of clinical trial data for EGFR-targeted therapies in HNSCC.

Main Results:

  • EGFR-targeted drugs (single agents or combined with chemotherapy/radiotherapy) show a good safety profile.
  • Antitumor activity observed in a subset of HNSCC patients.
  • Predictors of response, such as skin toxicity and EGFR gene polymorphisms (intron 1 CA repeats), are being investigated.

Conclusions:

  • EGFR-targeted therapies are a viable option for HNSCC treatment, demonstrating safety and activity.
  • Further research is needed to elucidate the biology of responsiveness to these agents.
  • Identifying predictive biomarkers is crucial for optimizing patient selection and treatment outcomes.

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...